Literature DB >> 7564344

Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits.

M Del Rio1, T Chulia, A Merchan-Perez, M Remezal, S Valor, J Gonzalez, J A Gutierrez, J A Contreras, M A Lasuncion, T Tejerina.   

Abstract

We examined the effect of indapamide (IND) on the development of atherosclerosis lesions in rabbits maintained on a 1% (wt/wt) cholesterol-enriched diet for a 16-week period. IND was supplemented to the diet at three different levels to correspond to doses of 0.1, 0.3, and 1 mg/kg/day. Throughout the treatment, dietary consumption and body weight gains were comparable among the experimental and control groups. IND had no significant effect on plasma cholesterol, triglycerides, or phospholipids concentrations. Despite the lack of effect of the drug on these parameters, its administration produced a tendency toward a reduction in the aortic content of cholesterol and a dose-dependent and significant decrease in aortic damage. In the aortic arch, the extent of intimal aortic surface covered by grossly discernible atherosclerotic lesions was decreased by IND 1 mg/kg/day from 11.02 +/- 1.10 to 6.00 +/- 1.00% (p < 0.05) and from 9.72 +/- 1.39 to 5.37 +/- 1.20% (p < 0.05) in the remaining thoracic sections. In addition, the former dose also reduced the number of lesions per square centimeter from 3.69 +/- 0.68 to 1.72 +/- 0.53% (p < 0.05), and from 3.37 +/- 0.85 to 1.55 +/- 0.46% (p < 0.05) in aortic arch and in thoracic sections, respectively. The possibility that IND reduces the development of atherosclerotic lesions produced by diet-induced hypercholesterolemia through a mechanism involving its calcium antagonist and/or its antioxidant activity is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564344     DOI: 10.1097/00005344-199506000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

Review 1.  Pharmacological properties of indapamide. Rationale for use in hypertension.

Authors:  A Bataillard; P Schiavi; J Sassard
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 2.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.